<DOC>
	<DOCNO>NCT02949830</DOCNO>
	<brief_summary>The purpose study determine long-term safety , tolerability pharmacokinetics ALN-AS1 AIP patient</brief_summary>
	<brief_title>A Study Evaluate Long-term Safety Clinical Activity ALN-AS1 Patient With Acute Intermittent Porphyria ( AIP )</brief_title>
	<detailed_description />
	<mesh_term>Porphyrias</mesh_term>
	<mesh_term>Porphyria , Erythropoietic</mesh_term>
	<mesh_term>Porphyria , Acute Intermittent</mesh_term>
	<criteria>Completed participation Part C study ALNAS1001 Not schedule regimen hemin Women child bear potential must negative serum pregnancy test , nursing , use acceptable contraception Willing able comply study requirement provide write informed consent Clinically significant abnormal laboratory result Received investigational agent ( ALNAS1 ) within 90 day first dose study drug followup another clinical study History multiple drug allergy intolerance subcutaneous injection</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>RNAi therapeutic</keyword>
	<keyword>Porphyria</keyword>
	<keyword>AIP</keyword>
	<keyword>Heme/Haem Arginate</keyword>
</DOC>